Thank you for confirming that you are based in a country where information about health claims for probiotics is permitted.

Meta-analysis of studies of over 19,000 babies have consistently shown a substantial reduction in necrotising enterocolitis, mortality and Late onset sepsis in premature babies recieving multistrain probiotics. A recent review showed a significant reduction in NEC and mortality in a UK NICU using Labinic Drops. Labinic has been used even in the most premature babies (22 weeks onwards) due to its excellent safety profile

A dose of Labinic of 0.2ml provides 2 billion probiotics which is the dose previously recommended by Deshpande et al

Exposure to antibiotics (either at Caesarean Section, through breast milk or from courses of antibiotics) can cause intestinal dybiosis. In addition, antacids (e.g. omeprazole, lanzoprazole) can also cause dysbiosis. This may present with abdominal pain, excessive/painful wind, diarrhoea and/or mucousy stools.

Labinic Drops can help to correct a dysbiosis and assist in the restoration of a more normal microbiome, with subsequent resolution of symptoms.

There are 3 strains of Bio-Flora (probiotics) present in equal quantities in Labinic Drops
Danisco Howaru Dophilus – Lactobacillus Acidophilus NCFM
Danisco Florafit Bifidobacterium bifidum Bb-06
Danisco Florafit Bifidobacterium infantis Bi-26

Labinic Drops represent great value. Labinic is manufactured to pharmaceutical standards and provides 2 billion probiotics for a very low daily price. How do we do it?

  • We don't employ expensive sales teams
  • We don't run costly marketing campaigns
  • We limit our attendance at conferences (some charge £'000s)
  • We don't have expensive literature and packaging
  • We manufacture in highly efficient facilities
  • Labinic is provided in a multi-dose bottle (like vitamins and iron) with no evidence that single-dose vials are necessary (over 1.5 million doses of Labinic safely given!)
  • The costs of NEC are substantial worldwide. In the USA, Johnson et al estimated the cost of medical NEC at $43-74,000 and surgical NEC (occuring 30% of cases) at $138-220,000, with the cost of short bowel syndrome over 5 years costing $1.5million per patient.

    In the UK as an example, the estimated costs are lower: surgical NEC is £54-71,000 per patient, and medical NEC is £21-37,000 (Renfrew et al). In 2013 575 cases of surgical NEC cost about £33m (ONS). The costs of sepsis are lower but significant. It is possible to assign costs of mortality and disability based on lost QALYs.

    Based on the meta-analysis reductions in NEC, mortality and sepsis, we estimate that if every premature baby born in the NHS (UK) at less than 34 weeks was given Labinic Drops once they had started milk feeds, and that Labinic was continued until 37 weeks corrected gestation, then the NHS could save £20 million every year (including the cost of the Labinic Drops).

    None of this includes the suffering and distress caused by these potentially modifiable conditions.

    Labinic Drops are not classified as medicines in the UK/EU and in some other jurisdictions. In others they have an intermediate classification. Labinic Drops are classified as food supplements with no health claims permitted.

    However Labinic Drops are manufactured to pharmaceutical standards. The facilities meet the international standards of Good Manufacturing Practice (GMP) and Good Pharmacy Practice (GPP) and are rated A-grade. Every batch undergoes pre- and post-production quality checks, to verify that they meet strict quality and safety standards. Certificates of Compliance and Certificates of Analysis are produced for every batch. Stability testing has been carried out so that the amount of live bacteria at the end of shelf-life continues to meet the Conformance Standards. All batches are checked to ensure there is no bacterial or fungal contamination prior to release as part of the Conformance Standards.

    Live bacterial preparations such as Labinic Drops should be handled and used with sensible precautions and care. Whilst they are generally recognised as safe, there are rare reported cases of infections arising from use of probiotics particularly in immunocompromised individuals, such as extremely preterm babies and patients receiving immune suppressants, patients with damaged intestinal tract (e.g. intestinal perforations and necrotising enterocolitis) where the live bacteria can enter the blood stream.

    No reports of infections have been reported from the use of Labinic Drops, and over 1.5 million doses have to date (2020) been given.

    In any patient who becomes unwell who is receiving Labinic Drops, the administration should be ceased immediately and appropriate investigations and treatment commenced. Labinic bacteria would normally be sensitive to combinations of Penicillin/Gentamicin, Ampicillin/Gentamicin, Meropenem/Vancomycin, Piptazobactam/Vancomycin, Cefotaxime/Vancomycin although the advice of a Pharmacist and Microbiologist should always be sought.

    United Kingdom NHS and private distribution of Labinic Drops in the UK is currently directly provided by Biofloratech Ltd

    European Union Labinic Drops are available from our distribution partners Miller and Miller and DrugsRus Ltd

    Australia and New Zealand Labinic Drops are available from our distribution partner Medsurge in Australia and New Zealand.

    Southern Africa Labinic Drops are available from our distribution partner Safeline in Southern Africa.

    Middle East and Hong Kong Labinic Drops are available from our distribution partner Miller and Miller.

    Office opening hours:
    10:00 to 16:30, Monday to Thursday
    10:00 to 15:00, Friday

    +44 (0)1932 506 181
    info@biofloratech.com

    Email is usually best for communication.

    Please leave a message if we are unable to answer.

    Further Information